First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study | Synapse
March 3, 2026Open Access
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study
Key Points
Patients receiving PD-1 blockade alongside TKIs show improved responses and overall survival rates.
Data reveals that combining therapies can optimize treatment for metastatic renal cell carcinoma.
Retrospective analysis across multiple centers provides a broad insight into real-world effectiveness.
Findings suggest a potential new standard for treating this challenging cancer type.